A new study from Bioethics International shows that a majority of drugs provided to very ill patients via the Food and Drug Administration’s (FDA) expanded access program – 76% – eventually gain marketing approval from FDA. However, few safety and efficacy data from expanded access uses are reported to the public before such approval. http://prn.to/2vtgDeN